Lysoway Therapeutics has developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These small-molecule compounds can restore autophagic flux and resolution, as well as enhance plasma membrane repair through direct activation of lysosomal exocytosis. These modulators have great potential to treat neurodegenerative diseases with age-related decline of autophagy/lysosomal function or rare diseases characterized by toxic accumulation of cellular wastes.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 245 1st St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lysoway.com
- Keywords
- Autophagy/lysosomal malfunction, Neurodegenerative diseases, lysosomal ion channels, Structure-based drug design.
- HQ
- Cambridge, MA
Lysoway Therapeutics Questions
Lysoway Therapeutics's website is http://www.lysoway.com
Lysoway Therapeutics's LinkedIn profile is https://www.linkedin.com/company/lysoway-therapeutics
Lysoway Therapeutics has
6 employees.
View email and phone details for 6
employees at Lysoway Therapeutics.
Lysoway Therapeutics's industry is
Biotechnology Research
Lysoway Therapeutics's top competitors are
The Silverstein Foundation For Parkinson's With Gba,
Dyne Therapeutics,
Tenvie Therapeutics,
Sisaf Ltd,
Denali Therapeutics,
Congruence Therapeutics,
Eumentis Therapeutics Inc.,
Threebrooks Therapeutics Inc,
Cellular Pharmacology - Sygnature Discovery,
Alkeus Pharmaceuticals, Inc..
Lysoway Therapeutics's categories are Biotechnology Research
Lysoway Therapeutics's founding year is 2020
